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Abstract  
Background:  An indwelling urinary catheter (IUC) is often inserted to manage bladder 
dysfunction but its impact on prognosis is uncertain.  We aimed to determine the association 
of IUC use on clinical outcomes after acute stroke in the international, multi-center, cluster 
crossover, Head Positioning in Acute Stroke Trial (HeadPoST). 
Methods:  Data were analyzed on HeadPoST participants (n=11,093) randomly allocated to 
the lying-flat or sitting-up head position.  Binomial, logistic regression, hierarchical mixed 
models were used to determine associations of early insertion of IUC within 7 days post-
randomization and outcomes of death or disability (defined as ‘poor outcome’, scores 3-6 on 
the modified Rankin scale) and any urinary tract infection (UTI) at 90 days with adjustment 
of baseline and post-randomization management covariates. 
Results:  Overall, 1167 (12%) patients had an IUC, but the frequency and duration of use 
varied widely across patients in different regions.  IUC use was more frequent in older 
patients, and those with vascular comorbidity, greater initial neurological impairment (on the 
National Institutes of Health stroke scale), and intracerebral hemorrhage as the underlying 
stroke type.  IUC use was independently associated with poor outcome (adjusted odds ratio 
[aOR] 1.40, 95% confidence interval [CI] 1.13-1.74), but not with UTI after adjustment for 
antibiotic treatment and stroke severity at hospital separation (aOR 1.13, 95% CI 0.59-2.18). 
The number exposed to IUC for poor outcome was 13. 
Conclusions:  IUC use is associated with a poor outcome after acute stroke. Further studies 
are required to inform appropriate use of IUC.  
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Bladder dysfunction is common after acute stroke, affecting at least one third of patients.1  A 
urodynamic study suggested frequencies of urinary incontinence of 73% and 64%, and 
urinary retention of 13% and 52%, in patients with acute intracerebral hemorrhage (ICH) and 
ischemic stroke, respectively.2  An indwelling urine catheter (IUC) is often inserted to 
manage these conditions3 but the benefits may be offset by increased mortality and morbidity, 
especially in the context of incontinence.4, 5  Guidelines6, 7 therefore recommend cautious use 
of IUC, and for their early removal to avoid urinary tract infection (UTI) and other sepsis.  
However, these recommendations are based on level C grade of evidence, since the data are 
derived from studies limited by small sample size, retrospective design, and incomplete 
adjustment for confounding.  We aimed to determine associations of IUC use and 90-day 
clinical outcomes in stroke patients with a broad range of characteristics who participated in 
the international Head Positioning in Acute Stroke Trial (HeadPoST).8 
Methods  
Study population  
HeadPoST was an international, multicenter, cluster crossover, clinical trial that involved 
11,093 adults (≥18 years) with acute stroke randomly allocated to the lying flat or sitting up 
head position soon at 114 hospitals in 9 countries from March 2015 to November 2016.8  A 
guardian consent process was used to implement the randomized intervention as a policy of 
usual service delivery to a pre-defined patient cluster; patients provided consent for use of 
their medical record data and centralized telephone follow-up.  HeadPoST is registered at 
ClinicalTrials.gov (NCT02162017).  
Procedures 
Demographic, medical history and clinical information, included the severity of neurological 
impairment on the National Institutes of Health Stroke Scale (NIHSS), were collected at 
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baseline.  Data of IUC use, including insertion date, along with other pre-defined 
management interventions, repeat NIHSS and an assessment of functional status on the 
simplified modified Rankin scale (mRS), were collected at Day 7 post-randomization (or at 
hospital separation if earlier).  Recorded IUC use was assumed as the first insertion after 
hospital admission and duration of use was censored at Day 7.  Trained staff, blind to 
treatment allocation, contacted patients not known to have died by telephone to assess their 
functional status on the mRS at 90-days.  The primary outcome for these analyses was death 
or dependency (mRS scores 3-6).  The secondary outcome was UTI identified from details 
related to serious adverse events (SAEs) reported by site investigators to the end of follow-up 
at 90 days.8 
Statistical analysis 
Binomial, logistic regression, hierarchical mixed models were used to adjust for the fixed 
effects of head position (lying-flat versus sitting-up) and cross-over period, random effects of 
cluster, and random interaction effects between cluster and crossover period.  The term 
‘unadjusted’ was used for convenience in defining this initial mixed model.  Potential 
confounders at baseline and Day 7 post-randomization (P value <0.2) in univariate analyses 
(Table 1; Supplemental Tables S1 and S2) defining associations of IUC and outcomes were 
included in sequential hierarchical logistic regression models with (model I) country groups 
according to region, (model II) baseline characteristics, and (model III) management 
covariates.  As the NIHSS and mRS scores at Day 7 (or earlier) were correlated (Spearman’s 
rank correlation=0.72), the former scale was used in model III to adjust for early neurological 
change.  As there was a high proportion of missing Day 90 mRS scores (12%), multiple 
imputation was conducted for a sensitivity analysis with all covariates (include outcome 
variable) in the mixed model for analysis (method was described in Supplemental Material).  
Considering UTI is an intermediate variable for IUC and poor functional outcome, an 
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additional sensitivity analysis was conducted to assess the strength of association in patients 
without UTI.  Pre-specified subgroup analyzes considered head position, age, sex, baseline 
neurological severity (NIHSS score), and medical history.  To assist in understanding the 
adverse consequences of IUC use, we calculated a number needed to expose for poor 
outcome using the adjusted odds ratio (aOR) obtained in models.9  Data are reported with 
95% confidence intervals (CI), and a two-sided P <0.05 was considered statistically 
significant.  All analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC). 
Data sharing  
Individual participant data used in these analyses can be shared by formal request with protocol 
from any qualified investigator to the Research Office of The George Institute for Global 
Health, Australia. 
Results 
Patient characteristics for IUC insertion 
Of the 11,093 randomized HeadPoST patients (mean age 68±14 years; 60% male), 1167 
(11.6%) had an IUC inserted during their hospitalization, but this figure varied widely across 
regions: highest for participants in India/Sri Lanka (33.8%), followed in decreasing frequency 
by those in South America, Australia/UK and China (including Taiwan) (Supplemental Table 
S3).  The median duration over 7 days of IUC insertion was 5 days (IQR 3-7) (Supplemental 
Table S3).   
Table 1 shows that the highest likelihood of IUC use was in older patients, and those with 
history of heart disease, greater initial neurological impairment, and a diagnosis of 
intracerebral hemorrhage (ICH).  In particular, most (70.7%) older patients (≥65 years) had 
an IUC.  Similarly, Day 7 data indicates that IUC use was related to greater neurological 
impairment and physical disability, defined by higher NIHSS and mRS scores, respectively.  
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Moreover, IUC use was more frequent after an admission to an intensive care or acute stroke 
unit, and in those who received antibiotics within the 7 days, as compared to those without an 
IUC (Table 1). 
IUC and outcomes 
Median duration of IUC use in patients with a poor outcome (death or dependency, mRS 3-6) 
was significantly higher than in those with good functional recovery (6 vs. 5 days, P=0.013; 
Supplemental Table S4).  Compared to patients without an IUC, those with IUC had a greater 
likelihood of a poor outcome (76.6% vs. 34.7%; P<0.0001; Supplemental Table S5).  Table 2 
shows that the increased odds of poor outcome with IUC use persisted after adjustment for 
imbalance in baseline characteristics and post-randomization management variables (Model 
III aOR 1.40, 95%CI 1.13-1.74), and after multiple imputation of missing outcome data (aOR 
1.36, 95% CI 1.14-1.63).  A significant interaction was found for IUC use and baseline 
NIHSS score (P for interaction 0.0019; Supplemental Figure S1).  The number needed to be 
exposed to an IUC for harm (death or dependency) was 13.   
Overall, only 0.7% (76/11093) patients had a UTI (Supplemental Table S5), and this was 
more likely in those with IUC (1.5% vs. 0.6%, P=0.0002; Supplemental Table S5).  The 
median time to diagnosis of UTI was 17 (IQR 5-36) days; but only 38% (29/76) of UTI 
events occurred within Day 7/discharge (Supplemental Figure S2).  However, in those 
patients with UTI, there was no clear difference in the median duration of IUC compared to 
those without UTI (4 [3-6] vs. 5 [3-7] days; P=0.17) (Supplemental Table S4).  Table 3 
shows this association in the initial adjusted analysis (model II, aOR 2.08, 95% CI 1.13-3.82), 
but lost significance after adjustment for post-randomization management variables that 
included antibiotic use and Day 7 (or hospital discharge) neurological severity (model III, 
aOR 1.13, 95% CI 0.59-2.18).  These associations remained after multiple imputation (model 
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III, OR 1.18, 95% CI 0.63-2.19).  In patients who received an IUC, duration of early use was 
not associated poor outcome (aOR 1.03, 95% CI 0.93-1.14; Supplemental Table S6).  
Subgroup analysis 
The odds of poor outcome being higher in females (P for interaction 0.01), the elderly 
(age >80 years; P for interaction 0.006), and those with mild neurological impairment 
(NIHSS scores of 0-4; P for interaction <0.0001) compared in other subgroups (Supplemental 
Figure S3).  No heterogeneity was found for stroke subtypes (P for interaction 0.47; 
Supplemental Figure S3), nor among subgroups for outcome in those with UTI 
(Supplemental Figure S4). 
Role of UTI on poor outcome 
Patients with UTI were more likely to have a poor 90-day outcome compared to those 
without UTI (71.9% vs. 39.0%; P<0.0001; Supplemental Table S2), but not after adjusting 
for all confounders (aOR 1.46, 95% CI 0.70-3.04; Supplemental Table S7).  The positive 
association of IUC and poor outcome persistent after including UTI as a confounder in the 
primary analysis (aOR 1.41, 95% CI 1.13-1.75; Supplemental Table S7).  Sensitivity analysis 
shows the positive association of IUC use and poor outcome was also present in patients 
without UTI, and of the same magnitude as identified in the primary analysis of the overall 
population (aOR 1.43, 95% CI 1.15-1.78; Supplemental Table S8).  
Discussion 
In these secondary analyses of a large population of patients with acute stroke, we have 
shown that inserting an IUC was associated with a poor functional outcome after adjusting 
for various prognostic and management confounders, including a diagnosis of UTI and early 
in-hospital antibiotic use.   
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Overall, approximately one in 10 stroke patients in our study had an IUC inserted, but the 
frequency was higher in the elderly and those with a history of heart disease, greater baseline 
neurological deficit, and ICH as the cause.  As such, the lower overall frequency of IUC in 
our study than reported in registries (20-30%)4, 5, 10 may reflect the selective nature of the 
clinical trial population which included patients with predominantly mild to moderate 
neurological severity, despite the pragmatic design and broad inclusion criteria.  Yet, our data 
are consistent with others in showing an association of IUC with increasing age and stroke 
severity.4, 11  Clearly, critical ill patients with more severe deficits are at increased risk of 
bladder dysfunction and adverse outcomes, and therefore, they require more intensive 
monitoring and interventional procedures, such as IUC insertion.  
Explanations for the adverse consequences of IUC insertion not so clear cut.5  While an IUC 
may compromise early mobilization and rehabilitation, and cause an inflammatory reaction 
from subclinical urosepsis.12  Another explanation for the significant association of IUC and 
poor outcome is indication bias, whereby patients at risk of poor recovery (old age or severe 
disability) are more likely to receive an IUC as part of their management.  Our subgroup 
analyses showed the adverse effect of IUC to be greater in patients with mild deficits (NIHSS 
scores 0-4) and early residual disability (mRS 0-2), suggesting caution in considering an IUC 
in such patients.  Protocols outlining indications and management of IUC may help reduce 
complications and improve outcomes.13, 14  Moreover, the finding elsewhere of females with 
poor functional stroke outcome15 having higher rates of inappropriate IUC use16 may explain 
our finding of sex differences in the prognostic significance of IUC. 
A recent meta-analysis has shown a wide frequency (3-44%) of UTI after stroke according to 
study design and setting.17  Once again, the low (0.7%) frequency of UTI in HeadPoST 
compared to an observational study18 may relate to selection and observer bias, and diagnosis 
based on reported SAEs rather than systematic surveillance.  However, our approach was 
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arguably more clinically relevant in using a ‘clinically significant’ endpoint and in showing 
attenuation of the association of IUC use and UTI after adjustment for antibiotic use and level 
of functional impairment.  Our finding are therefore contrary to a previous hospital-based 
study showing a significant association of IUC and UTI,19 but these results were based on 
small sample where UTIs were reported without standard diagnostic criteria and there was no 
adjustment for other variables, such as antibiotic use.  Our study also contrasts with another 
study which found an association of UTI and poor functional outcome (mRS 3-5) at the time 
of hospital discharge,20 but is consistent with another study where adjustments were made for 
prognostic covariates.5  Nonetheless, we recognize that the small number of cases of UTI in 
our study restricted our ability to undertake stratified analyzes or adjust for a large number 
covariates.  
Strengths of our study include the large sample size of participants with a broad range of 
characteristics managed in a range of health care settings.  Moreover, we were able to adjust 
for a large number of potential confounding prognostic factors in different multivariable 
models.  However, in any observational study there is the potential for incomplete 
adjustment, while the lack of systematic screening for UTI and reliance on SAE data, likely 
biased reported events towards those that were more clinically significant or symptomatic.  
We also had very limited information of the type of IUCs used, their indication, timing of 
removal, and relationship in the use of antibiotics. The data of censored assessment of all 
hospital management also limited the utility analysis of IUC duration and outcomes. 
In summary, IUC use is associated with a poor functional outcome after acute stroke, after 
adjustment for a range of important prognostic and management factors.  Further studies are 
required to establish causal pathways and inform guideline recommendations regarding the 
appropriate indications for IUC to decreases potential risks and promote recovery in 
vulnerable patients. 
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Table 1.  Characteristics of 11093 patients by urinary catheter use  
 Urinary catheter inserted  
Characteristics  
Yes 
(N=1167) 
No 
(N=9829) 
P value* 
Age, years 71.3 ± 13.9 67.5 ±13.7 <0.0001 
Male 610 (52.3) 5999 (61.0) <0.0001 
Region   <0.0001 
   Australia/UK 535 (45.8) 4154 (42.3)  
   China (incl. Taiwan) 266 (22.8) 4371 (44.5)  
   India/Sri Lanka 259 (22.2) 507 (5.2)  
   South America 107 (9.2) 797 (8.1)  
Hypertension 630 (54.0) 4948 (50.3) 0.140 
Previous stroke 272 (23.3) 2314 (23.5) 0.854 
Coronary artery disease 192 (16.5) 1337 (13.6) 0.008 
Atrial fibrillation 227 (19.5) 936 (9.5) <0.0001 
Heart failure 70 (6.0) 337 (3.4) <0.0001 
Diabetes mellitus 252 (21.6) 1956 (20.0) 0.642 
Stroke category   <0.0001 
   AIS 950 (81.5) 8442 (86.1)  
   ICH 192 (16.5) 728 (7.4)  
   Uncertain 24 (2.1) 637 (6.5)  
NIHSS at admission 12.0 (6.0, 18.0) 4.0 (2.0, 7.0) <0.0001 
GCS score at admission 14.0 (11.0, 15.0) 15.0 (14.0, 15.0) <0.0001  
Pre-morbid mRS 0-1† 881 (75.5) 7782 (79.2) 0.008 
NIHSS at 7 days 9.0 (4.0, 16.0) 2.0 (1.0, 5.0) <0.0001 
mRS at 7 days 4.0 (3.0, 5.0) 2.0 (1.0, 3.0) <0.0001 
ICU admission 242 (20.7) 274 (2.8) <0.0001 
ASU admission 824 (70.6) 5716 (58.2) <0.0001 
Antibiotic treatment 526 (45.1) 1146 (11.7) <0.0001 
Underwent surgery‡  29 (2.5) 7 (0.1) <0.0001 
Data are n (%), mean (SD) and median (IQR). 
AIS denotes acute ischaemic stroke, ASU acute stroke unit, GCS Glasgow coma scale, ICH 
intracerebral hemorrhage, ICU intensive care unit, mRS modified Rankin scale, NIHSS 
National Institutes of Health Stroke Scale. 
*P values from the Student’s t-test or Wilcoxon rank sum test for continuous variables, and 
the Chi-squared test or Fisher’s extract test for categorical variables.   
†Estimated functional grade score 0-1 on the mRS 
‡Includes decompressive hemicraniectomy, open craniotomy, minimally invasive surgery and 
intraventricular drainage of ICH. 
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Table 2. Association of urinary catheter use and death or dependency at 90 days 
Model  Complete case dataset  Multiple imputation dataset 
 aOR (95% CI)  P value  aOR (95% CI) P value 
Unadjusted* 5.44 (4.54-6.39) <0.0001  5.17 (4.44-6.02) <0.0001 
Model I† 5.27 (4.49-6.18) <0.0001  5.01 (4.31-5.83) <0.0001 
Model II‡ 2.31 (1.91-2.78) <0.0001  2.21 (1.85-2.64) <0.0001 
Model III§ 1.40 (1.13-1.74) 0.002  1.36 (1.14-1.63) 0.001 
aOR denotes adjusted odds ratio, CI confidence interval 
*Binomial logistic regression model with adjustment for the fixed effects of head 
position (lying-flat versus sitting-up) and crossover period, and random effects of 
cluster, and random interaction effects between cluster and crossover period. 
†Model I adjusted for region (Australia/UK, China including Taiwan, India/Sri 
Lanka, South America) 
‡Model II is model I with further adjustment for baseline covariates of age as a 
continuous variable, sex, estimated premorbid grade 0 or 1 on the modified Rankin 
scale (mRS), baseline National Institutes of Health Stroke Scale (NIHSS) score as a 
continuous variable, history of heart disease (any heart failure, atrial fibrillation or 
coronary artery disease), diabetes mellitus or stroke, and pathological stroke type.  
§Model III is model II further adjusted for individual variables at Day 7 or earlier 
hospital separation, including intensive care unit (ICU) admission, acute stroke unit 
(ASU) admission, antibiotic use, and NIHSS score as a continuous variable. 
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Table 3.  Association of urinary catheter use and urinary tract infection within 90 days  
Model  Original dataset  Multiple imputation 
 aOR (95% CI)  P value  aOR (95% CI) P value 
Unadjusted* 2.85 (1.62-4.99) 0.0003  2.85 (1.62-4.99) 0.0003 
Model I† 2.58 (1.47-4.53) 0.001  2.58 (1.47-4.53) 0.001 
Model II‡ 2.08 (1.13-3.82) 0.018  2.05 (1.12-3.75) 0.020 
Model III§ 1.13 (0.59-2.18) 0.707  1.18 (0.63-2.19) 0.610 
aOR denotes adjusted odds ratio, CI confidence interval 
*Binomial logistic regression model with adjustment for the fixed effects of head position 
(lying-flat versus sitting-up) and crossover period, and random effects of cluster, and random 
interaction effects between cluster and crossover period. 
†Model I adjusted for region (Australia/UK, China including Taiwan, India/Sri Lanka, and 
South America) 
‡Model II is model I with further adjustment for baseline covariates of age as a continuous 
variable, sex, estimated premorbid grade 0 or 1 on the modified Rankin scale (mRS), baseline 
National Institutes of Health Stroke Scale (NIHSS) score as a continuous variable, history of 
heart disease (any heart failure, atrial fibrillation or coronary artery disease), diabetes mellitus 
or stroke, and pathological stroke type.  
§Model III is model II further adjusted for individual variables at Day 7 or earlier hospital 
separation, including intensive care unit (ICU) admission, acute stroke unit (ASU) admission, 
antibiotic use, and NIHSS score as a continuous variable. 
 
 
 
 
 
